K. Kittel

1.3k total citations
12 papers, 243 citations indexed

About

K. Kittel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. Kittel has authored 12 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. Kittel's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (7 papers) and Neutropenia and Cancer Infections (2 papers). K. Kittel is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (7 papers) and Neutropenia and Cancer Infections (2 papers). K. Kittel collaborates with scholars based in Germany, Australia and Switzerland. K. Kittel's co-authors include Gϋnter von Minckwitz, Holger Eidtmann, Sibylle Loibl, Iris Schrader, Jens Huober, Hans Tesch, Christine Solbach, Holm Eggemann, Jens‐Uwe Blohmer and Michael Untch and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

K. Kittel

12 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Kittel Germany 7 180 142 77 38 38 12 243
Paw Christian Holdgaard Denmark 7 107 0.6× 116 0.8× 120 1.6× 31 0.8× 32 0.8× 15 252
Tetsuhiro Yoshinami Japan 6 116 0.6× 50 0.4× 53 0.7× 33 0.9× 22 0.6× 48 174
Vassilena Tsvetkova Italy 7 181 1.0× 123 0.9× 65 0.8× 18 0.5× 41 1.1× 14 242
Laura L. Michel Germany 9 120 0.7× 72 0.5× 60 0.8× 32 0.8× 14 0.4× 37 194
Shirley Sundersingh India 9 84 0.5× 80 0.6× 64 0.8× 119 3.1× 30 0.8× 33 237
G. A. Dashyan Russia 4 228 1.3× 275 1.9× 86 1.1× 13 0.3× 79 2.1× 22 320
David Papadimos Australia 8 87 0.5× 43 0.3× 70 0.9× 62 1.6× 30 0.8× 11 205
Christa Balanoff United States 7 180 1.0× 99 0.7× 37 0.5× 14 0.4× 46 1.2× 30 262
M.A. Vicente Conesa Spain 4 265 1.5× 47 0.3× 44 0.6× 28 0.7× 13 0.3× 9 318
Phuong Vu Norway 7 139 0.8× 106 0.7× 64 0.8× 107 2.8× 23 0.6× 12 258

Countries citing papers authored by K. Kittel

Since Specialization
Citations

This map shows the geographic impact of K. Kittel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Kittel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Kittel more than expected).

Fields of papers citing papers by K. Kittel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Kittel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Kittel. The network helps show where K. Kittel may publish in the future.

Co-authorship network of co-authors of K. Kittel

This figure shows the co-authorship network connecting the top 25 collaborators of K. Kittel. A scholar is included among the top collaborators of K. Kittel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Kittel. K. Kittel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Wroblewski, Mark, Janna-Lisa Velthaus, Volkmar Müller, et al.. (2017). Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.. Journal of Clinical Oncology. 35(15_suppl). 11522–11522. 1 indexed citations
2.
Untch, Michael, Gϋnter von Minckwitz, B. Gerber, et al.. (2015). 1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). European Journal of Cancer. 51. S264–S264. 1 indexed citations
3.
Otremba, Burkhard, et al.. (2015). 1570 The compatibility of biosimilar filgrastim under cytotoxic chemotherapy in the treatment of malignant diseases: VENICE study. European Journal of Cancer. 51. S227–S227. 1 indexed citations
4.
Darb‐Esfahani, Silvia, Gϋnter von Minckwitz, Carsten Denkert, et al.. (2014). Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 14(1). 546–546. 67 indexed citations
5.
Gerber, Bernd, Gϋnter von Minckwitz, Holger Eidtmann, et al.. (2014). Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). Annals of Surgical Oncology. 21(8). 2517–2524. 16 indexed citations
6.
Gerber, B., Sibylle Loibl, Holger Eidtmann, et al.. (2013). Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Annals of Oncology. 24(12). 2978–2984. 105 indexed citations
7.
Eidtmann, Holger, K. Kittel, Mahdi Rezai, et al.. (2011). P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab.. Cancer Research. 71(24_Supplement). P1–14. 2 indexed citations
8.
Huober, Jens, C Hanusch, PA Fasching, et al.. (2011). S3-6: Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: Results of the Non-Responder Part of the GEPARQUINTO Study (GBG 44).. Cancer Research. 71(24_Supplement). S3–6. 6 indexed citations
9.
Gerber, B., Holger Eidtmann, Peter A. Fasching, et al.. (2011). Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).. Journal of Clinical Oncology. 29(15_suppl). 1006–1006. 23 indexed citations
10.
11.
Schmid, Peter, R. Kreienberg, Peter Klare, et al.. (2008). Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemotherapy and Pharmacology. 64(2). 401–406. 10 indexed citations
12.
Heilmann, V., Holm Eggemann, G. Heinrich, et al.. (2005). Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 753–753. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paw Christian Holdgaard Breakdown of academic impact, for papers by Tetsuhiro Yoshinami Breakdown of academic impact, for papers by Vassilena Tsvetkova Breakdown of academic impact, for papers by Laura L. Michel Breakdown of academic impact, for papers by Shirley Sundersingh Breakdown of academic impact, for papers by G. A. Dashyan Breakdown of academic impact, for papers by David Papadimos Breakdown of academic impact, for papers by Christa Balanoff Breakdown of academic impact, for papers by M.A. Vicente Conesa Breakdown of academic impact, for papers by Phuong Vu
Rankless by CCL
2026